2H-2023: XACIATO First commercial sale ; Ovaprene Initiation of enrollment in pivotal contraceptive study conducted with NICHD; Sildenafil Cream, 3.6% Preparation for end-of-Phase 2 meeting with FDA; DARE-PDM1 Announcement of topline results of Phase 1 clinical study; DARE-VVA1 IND preparation and other activities to allow initiation of Phase 2 clinical study; DARE-HRT1 IND preparation and other activities to allow initiation of Phase 3 clinical study
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DARE:
- Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
- Dare Bioscience announces publication of data from Phase 1/2 study of DARE-HRT1
- Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
- DARE Upcoming Earnings Report: What to Expect?
- Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023